Resmed share price dips despite profit and dividend boost

Profits and dividends are up, so why is the Resmed share price down?

| More on:
a young woman props her hand under the face as she pokes her head out from under a luxurious doona in a bedroom decorated with flowers and a stylish lamp.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

sdf

Key points

  • The Resmed share price is down 3.5% in afternoon trading
  • The US-based company booked a 12% increase in revenue and a 9% increase in profit year over year 
  • Holders of Resmed shares on the ASX will receive 4.4 US cents per share as dividends on September 22

The Resmed CDI (ASX: RMD) share price is down around 3.5% at $33.42 in afternoon trading. This comes after the US-based sleep apnoea medical device company released its full-year results to the ASX this morning.

As my colleague James wrote, ResMed Inc (NYSE: RMD) booked a 12% increase in revenue year over year to US$3.6 billion. It finished the year with an underlying net profit of US$850.8 million, up 9% on FY21.

Revenue and profits up

As James points out, ResMed's underlying net profit was slightly above market consensus expectations of US$825.6 million.

A recall by competitor Royal Philips in June 2021 provided a revenue boost for ResMed in FY22.

Management estimates that US$60 million to US$70 million in incremental fourth-quarter revenue was related to the recall. That implies an annual total of US$220 million to US$260 million.

Inflation started to bite in FY22, with higher freight and manufacturing costs impacting margins.

Over FY22, the Resmed share price slipped by about 7%.

Resmed dividends up

ResMed declared a final quarterly cash dividend of 44 US cents, up 5% on the prior corresponding period. But that's what ResMed Inc shareholders (owners of the NYSE-listed shares) will get. It's different for ASX shareholders, who own Resmed CDI shares.

Remember ResMed is a US-domiciled company listed on the New York Stock Exchange. The Resmed shares listed on the ASX are CHESS depositary interests (CDIs) which "confer a beneficial interest in the underlying financial product to which it relates", explains the ASX.

This beneficial interest is on a ratio of 10:1 for owners of the ASX shares. So, Resmed CDI shareholders will receive 4.4 US cents per share as dividends. This currently converts to 6.2 cents in Australian currency. The payment date is 22 September.

So, why is the Resmed share price down?

The company exceeded consensus profit expectations, and it's going to pay a higher dividend this year. So why is the Resmed share price down?

Well, the dip might not have anything to do with investors' reactions to the results. The market as a whole is down today.

The S&P/ASX 200 Index (ASX: XJO) is off 0.73% and the S&P/ASX 200 Health Care Index (ASX: XHJ) is down 1.81%.

In fact, healthcare is the second worst performing sector today behind the S&P/ASX 200 A-REIT Index (ASX: XPJ), which is down 1.87%. The only sectors in the green are energy and communications.

So, it might simply be a case of the Resmed share price being dragged down, along with many other ASX healthcare shares, by the broader sector and market today.

Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed Inc. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed Inc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Happy healthcare workers in a labs
Healthcare Shares

Macquarie initiates coverage of Neuren Pharmaceuticals shares; forecasts 45% upside

The broker described Neuren as a standout in the ASX biotech sector.

Read more »

A woman leans forward with her hand behind her ear, as if trying to hear information.
Healthcare Shares

Does Macquarie think Cochlear shares are a buy, hold, or sell?

Macquarie has released a new note on Cochlear following the company's FY25 profit guidance change.

Read more »

Stethoscope with a piggy bank in the middle.
Healthcare Shares

Up 18% this year, does Macquarie expect NIB shares to go higher?

This expert has a bold prediction for NIB.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why is the Mesoblast share price up 11% in June?

The ASX biotech share reached a 10-week high of $1.94 today.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Up 51% since the tariff pain, is it too late to buy Pro Medicus shares?

After rocketing higher, is the ASX healthcare share still an opportunity?

Read more »

A woman wearing a yellow shirt smiles as she checks her phone.
Healthcare Shares

CSL shares push higher on US FDA approval

This biotech giant has been given a boost in the United States.

Read more »

A man holds his hand under his chin as he concentrates on his laptop screen and reads about the ANZ share price
Healthcare Shares

Up 29% this year, does Macquarie expect Medibank Private shares to continue rising?

Medibank's explosive share price growth has caught the eye of this broker.

Read more »

Man in business suit carries box of personal effects
Healthcare Shares

Monash IVF shares jump 9% as CEO quits after second embryo incident

Two incidents at its clinics have cost this CEO his job.

Read more »